Benjamin Burnett Analyst Performance

Analyst at Wells Fargo & Company

Benjamin Burnett is a stock analyst at Wells Fargo & Company in the medical sector, covering 15 publicly traded companies. Over the past year, Benjamin Burnett has issued 13 stock ratings, including strong buy, buy, and hold recommendations. While full access to Benjamin Burnett's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Benjamin Burnett's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 25 Last 6 Years
Buy Recommendations: 64.00% 16 Buy Ratings
Companies Covered: 15 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	8.0%	2 ratings
Buy	56.0%	14 ratings
Hold	36.0%	9 ratings
Sell	0.0%	0 ratings

Out of 25 total stock ratings issued by Benjamin Burnett at Wells Fargo & Company, the majority (56.0%) have been Buy recommendations, followed by 36.0% Hold and 8.0% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
BLUE
Mar 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
EFTR
Nov 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	15 companies

Benjamin Burnett, an analyst at Wells Fargo & Company, currently covers 15 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 15 companies	100.0%

Benjamin Burnett of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 9 companies	60.0%
MED - DRUGS 2 companies	13.3%
PHARMACEUTICAL PREPARATIONS 2 companies	13.3%
BIOTECHNOLOGY 1 company	6.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	6.7%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CNTA Centessa Pharmaceuticals	9/3/2025	Initiated Coverage	$17.27	$31.00	Overweight
XENE Xenon Pharmaceuticals	9/3/2025	Initiated Coverage	$39.30	$48.00	Overweight
ALKS Alkermes	9/3/2025	Upgrade	$30.00		Strong-Buy
AVDL Avadel Pharmaceuticals	9/3/2025	Upgrade	$14.66		Hold
AXSM Axsome Therapeutics	9/3/2025	Upgrade	$122.00		Strong-Buy
AXSM Axsome Therapeutics	9/2/2025	Initiated Coverage	$123.47	$163.00	Overweight
AVDL Avadel Pharmaceuticals	9/2/2025	Initiated Coverage	$14.98	$16.00	Equal Weight
ALKS Alkermes	9/2/2025	Initiated Coverage	$29.40	$44.00	Overweight
RVMD Revolution Medicines	4/1/2025	Lower Price Target	$35.36	$64.00	Buy
FATE Fate Therapeutics	3/6/2025	Lower Price Target	$0.98	$3.00	Hold
RVMD Revolution Medicines	2/27/2025	Lower Price Target	$40.94	$78.00	Buy
CRSP CRISPR Therapeutics	2/13/2025	Lower Price Target	$42.61	$49.00	Hold
IRON Disc Medicine	1/24/2025	Boost Price Target	$57.07	$94.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.